Management of Thyroid Nodules with Nuclear Atypia

Introduction to Nuclear Atypia Management

The American College of Surgeons and the National Comprehensive Cancer Network recommend that for an adult patient with a thyroid nodule showing atypia of undetermined significance with nuclear atypia on FNA, proceed directly to surgical resection or pursue molecular testing to further stratify risk 1

The presence of nuclear atypia on cytology, as assessed by the American Thyroid Association, confers a high malignancy risk, with a range of 42-79% 1
The American Thyroid Association suggests that the combination of nuclear atypia on cytology plus high-risk ultrasound features independently increases malignancy risk 1

The National Comprehensive Cancer Network recommends assessing the nodule's ultrasound characteristics using ATA sonographic patterns to guide management, with high-risk features prompting direct surgery 1
The American College of Radiology and the National Comprehensive Cancer Network suggest that molecular diagnostics, such as BRAF V600E mutation testing, may reclassify AUS nodules as more or less likely malignant, with 100% specificity for papillary thyroid carcinoma 1

The American Thyroid Association and the National Comprehensive Cancer Network recommend that for nodules with nuclear atypia, the surgical approach depends on the extent of disease, with lobectomy acceptable for unifocal disease <4 cm without suspicious lymphadenopathy 1
The National Comprehensive Cancer Network suggests that total thyroidectomy is recommended if BRAF mutation is confirmed, bilateral nodules are present, or suspicious cervical lymph nodes are identified on preoperative ultrasound 1

The American Academy of Otolaryngology-Head and Neck Surgery and the National Comprehensive Cancer Network recommend considering high-risk clinical factors, such as history of head and neck irradiation, family history of thyroid cancer, and age <15 years or male gender, which lower the threshold for immediate surgery 1, 2
The National Comprehensive Cancer Network suggests measuring serum calcitonin to screen for medullary thyroid carcinoma, which has higher sensitivity than FNA alone 1, 3